The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency

Journal of Thoracic Oncology

Volumn 12, Issue 8, 2017, Pages 1210-1222

  Cressman, Sonya ^a,b   Peacock, Stuart J ^a,b,c   Tammemägi, Martin C ^d   Evans, William K ^e,f   Leighl, Natasha B ^g,h   Goffin, John R ^f,i   Tremblay, Alain ^j   Liu, Geoffrey ^g,h   Manos, Daria ^k   MacEachern, Paul ^j,l   Bhatia, Rick ^m   Puksa, Serge ^f,i   Nicholas, Garth ⁿ   McWilliams, Annette ^o,p   Mayo, John R ^q,r   Yee, John ^q,r   English, John C ^q,r   Pataky, Reka ^a,b,q   McPherson, Emily ^s   Atkar Khattra, Sukhinder ^b   Johnston, Michael R ^t,u   Schmidt, Heidi ^g   Shepherd, Frances A ^g,h   Soghrati, Kam ^v   Amjadi, Kayvan ⁿ   Burrowes, Paul ^l   Couture, Christian ^w   Sekhon, Harmanjatinder S ⁿ   Yasufuku, Kazuhiro ^h   Goss, Glenwood ⁿ   Ionescu, Diana N ^b   Hwang, David M ^g   Martel, Simon ^w   Sin, Don D ^x   Tan, Wan C ^x   Urbanski, Stefan ^l   Xu, Zhaolin ^k   Tsao, Ming Sound ^g,h   Lam, Stephen ^b,q   more..

^a Canadian Centre for Applied Research in Cancer Control   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d BROCK UNIVERSITY   (Canada)

^e CANCER CARE ONTARIO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ JURAVINSKI CANCER CENTRE   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^l FOOTHILLS HOSPITAL   (Canada)

^m MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

ⁿ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^o FIONA STANLEY HOSPITAL   (Australia)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r VANCOUVER GENERAL HOSPITAL   (Canada)

^s MATHEMATICA POLICY RESEARCH   (United States)

^t Beatrice Hunter Cancer Research Institute   (Canada)

^u DALHOUSIE UNIVERSITY   (Canada)

^v CREDIT VALLEY HOSPITAL   (Canada)

^w UNIVERSITÉ LAVAL   (Canada)

^x ST PAUL S HOSPITAL   (Canada)

more..

Author keywords

Cost effectiveness; Economics; Lung cancer screening; Screening operations

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANADA; CANCER MORTALITY; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST CONTROL; EARLY DIAGNOSIS; EDUCATION; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LOW RISK PATIENT; LUNG CANCER; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SMOKING; THORAX RADIOGRAPHY; VERY ELDERLY; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; INCIDENCE; LUNG TUMOR; MASS SCREENING; PATHOLOGY; RETROSPECTIVE STUDY;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85020001005     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.04.021     Document Type: Article

References (41)

1. International Early Lung Cancer Action Program Investigators, Henschke, C.I., Yankelevitz, D.F., et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006), 1763–1771.
2. Sone, S., Takashima, S., Li, F., et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351 (1998), 1242–1245.
3. National Lung Screening Trial Research Team, Aberle, D.R., Berg, C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
4. Moyer, V.A. US Preventive Services Task Force, Le Fevre, M.L., et al. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Inter Med 160 (2014), 330–338.
5. Centers for Medicare and Medicaid Services. Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. Accessed June 1, 2016.
6. Lewin, G., Morisette, K., Dickinson, J., et al. Recommendations on screening for lung cancer. CMAJ 188 (2016), 425–432.
7. Ma, J., Ward, E.M., Smith, R., Jemal, A., Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 119 (2013), 1381–1385.
8. Roth, J.A., Sullivan, S.D., Goulart, B.H., Ravelo, A., Sanderson, J.C., Ramsey, S.D., Projected clinical, resource use, and fiscal impacts of implementing low-dose computed tomography lung cancer screening in Medicare. J Oncol Pract 11 (2015), 267–272.
9. Goulart, B.H., Bensink, M.E., Mummy, D.G., Ramsey, S.D., Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Cancer Netw 10 (2012), 267–275.
10. Wu, G.X., Goldstein, L., Kim, J.Y., Raz, D.J., Proportion of non-small-cell lung cancer patients that would have been eligible for lung cancer screening. Clin Lung Cancer 17 (2016), e131–e139.
11. Ali, N., Lifford, K.J., Carter, B., et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open, 5, 2015, 3008254.
12. Tammemägi, M.C., Application of risk prediction models to lung cancer screening: a review. J Thorac Imaging 30 (2015), 88–100.
13. Tammemägi, M.C., Katki, H.A., Hocking, W.G., et al. Selection criteria for lung-cancer screening. N Engl J Med 368 (2013), 728–736.
14. Tammemägi, M.C., Church, T.R., Hocking, W.G., et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med, 11, 2014, e1001764.
15. Ten Haaf, K., Jeon, J., Tammemägi, M.C., et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med, 14, 2017, e1002277.
16. Black, C., Bagust, A., Boland, A., et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 10 (2006), 1–90.
17. Canadian Agency for Drugs and Technologies in Health. Low-dose computed tomography for lung cancer screening: a review of the clinical effectiveness, diagnostic accuracy, cost-effectiveness, and guidelines. http://www.ncbi.nlm.nih.gov/books/NBK350016/. Accessed June 1, 2016.
18. Chirikos, T.N., Hazelton, T., Tockman, M., Clark, R., Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 121 (2002), 1507–1514.
19. Shmueli, A., Fraifeld, S., Peretz, T., et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. Value Health 16 (2013), 922–931.
20. Manser, R., Dalton, A., Carter, R., Byrnes, G., Elwood, M., Campbell, D.A., Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer 48 (2005), 171–185.
21. Villanti, A.C., Jiang, Y., Abrams, D.B., Pyenson, B.S., A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PloS One, 8, 2013, e71379.
22. Whynes, D.K., Could CT screening for lung cancer ever be cost effective in the United Kingdom?. Cost Eff Resour Alloc, 6, 2008, 5.
23. Mcmahon, P.M., Kong, C.Y., Bouzan, C., et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 6 (2011), 1841–1848.
24. Goffin, J.R., Flanagan, W.M., Miller, A.B., et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol 1 (2015), 807–813.
25. Mahadevia, P.J., Fleisher, L.A., Frick, K.D., Eng, J., Goodman, S.N., Powe, N.R., Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289 (2003), 313–322.
26. Raymakers, A.J., Mayo, J., Lam, S., FitzGerald, J.M., Whitehurst, D.G., Lynd, L.D., Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review. Appl Health Econ Health Policy 14 (2016), 409–418.
27. National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 102 (2010), 1771–1779.
28. Marcus, P.M., Lenz, S., Sammons, D., Black, W., Garg, K., Recruitment methods employed in the National Lung Screening Trial. J Med Screen 19 (2012), 94–102.
29. Tammemägi, C.M., Berg, C.D., Riley, T.L., Cunningham, C.R., Taylor, K.L., Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 103 (2011), 1058–1068.
30. Oken, M.M., Hocking, W.G., Kvale, P.A., et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306 (2011), 1865–1873.
31. Statistics Canada. Table 102-0551—Deaths and mortality rate, by selected grouped causes, age group and sex, Canada, annual, CANSIM (database). http://www5.statcan.gc.ca/. Accessed June 1, 2016.
32. Tramontano, A.C., Schrag, D.L., Malin, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Med Decis Making 35 (2015), 371–387.
33. Jang, R.W., Isogai, P.K., Mittmann, N., et al. Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol 5 (2010), 1953–1957.
34. McWilliams, A., Tammemägi, M.C., Mayo, J.R., et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 369 (2013), 910–919.
35. Ostroff, J.S., Goffin, J.R., Khuri, F.R., Warren, G.W., Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation. J Oncol Pract 12 (2016), 55–58.
36. Postolache, P., Nemes, R.M., Petrescu, O., Merisanu, I.O., Smoking cessation, pulmonary rehabilitation and quality of life at smokers with COPD. Rev Med Chir Soc Med Nat Iasi 119 (2015), 77–80.
37. Tanner, N.T., Kanodra, N.M., Gebregziabher, M., et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 193 (2016), 534–541.
38. Chiles, C., Duan, F., Gladish, G.W., et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. Radiology 276 (2015), 82–90.
39. Cressman, S., Lam, S., Tammemägi, C.M., et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol 9 (2014), 1449–1458.
40. Cipriano, L.E., Romanus, D., Earle, C.C., et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 14 (2011), 41–52.
41. Tanner, N.T., Gebregziabher, M., Halbert, C.H., Payne, E., Egede, L.E., Silvestri, G.A., Racial differences in outcomes within the National Lung Screening Trial. Implications for widespread implementation. Am J Respir Crit Care Med 192 (2015), 200–208.